7月13日 - ** 生物技术公司Ocugen（OCGN.O）股价上涨2%，收于1.49美元
** 该公司表示，已同意在中东和北非地区授权其用于治疗视网膜色素变性的实验性基因疗法OCU400。视网膜色素变性是一种罕见的遗传性眼病，会导致视力逐渐丧失
** 与Roots Pharmaceutical及其合作伙伴Al-Dhow International Holding达成的协议包括最高400万美元的预付款和早期研发付款
** Ocugen 最高可获得 2.55 亿美元的销售里程碑付款，并享有净销售额 22% 的专利使用费，同时将向合作伙伴供应 OCU400
** 公司表示预计将在未来三个月内敲定该协议
** OCU400目前正处于后期临床试验阶段，预计2027年初公布数据，并计划随后提交监管申请
** 截至上一交易日收盘，该股年内累计涨幅约为9%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.